Meridian Bioscience analyst ratings
Meridian Bioscience analyst ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/08/2022 | 2.19% | HC Wainwright & Co. | $30 → $34 | Downgrades | Buy → Neutral |
| 02/07/2022 | -9.83% | HC Wainwright & Co. | $28 → $30 | Maintains | Buy |
| 11/15/2021 | -15.84% | HC Wainwright & Co. | $27 → $28 | Maintains | Buy |
| 08/09/2021 | -18.85% | HC Wainwright & Co. | $30 → $27 | Maintains | Buy |
| 05/10/2021 | -9.83% | HC Wainwright & Co. | $32 → $30 | Maintains | Buy |
| 02/24/2021 | -3.82% | HC Wainwright & Co. | $34 → $32 | Maintains | Buy |
| 02/08/2021 | 2.19% | HC Wainwright & Co. | $30 → $34 | Maintains | Buy |
| 11/16/2020 | -9.83% | HC Wainwright & Co. | $34 → $30 | Maintains | Buy |
| 07/27/2020 | 2.19% | HC Wainwright & Co. | → $34 | Initiates Coverage On | → Buy |
| 05/01/2019 | -72.95% | Canaccord Genuity | $11 → $9 | Maintains | Sell |
| 05/01/2019 | -66.94% | Piper Sandler | $15 → $11 | Upgrades | Underweight → Neutral |
| 04/03/2019 | — | Canaccord Genuity | Downgrades | Hold → Sell | |
| 01/26/2018 | -51.91% | Canaccord Genuity | $14 → $16 | Maintains | Hold |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 07/08/2022 | 2.19% | HC Wainwright & Co. | 30 美元 → 34 美元 | 降级 | 买入 → 中性 |
| 2022 年 7 月 2 日 | -9.83% | HC Wainwright & Co. | 28 美元 → 30 美元 | 维持 | 购买 |
| 11/15/2021 | -15.84% | HC Wainwright & Co. | 27 美元 → 28 美元 | 维持 | 购买 |
| 2021 年 9 月 8 日 | -18.85% | HC Wainwright & Co. | 30 美元 → 27 美元 | 维持 | 购买 |
| 2021 年 10 月 5 日 | -9.83% | HC Wainwright & Co. | 32 美元 → 30 美元 | 维持 | 购买 |
| 2021 年 2 月 24 日 | -3.82% | HC Wainwright & Co. | 34 美元 → 32 美元 | 维持 | 购买 |
| 02/08/2021 | 2.19% | HC Wainwright & Co. | 30 美元 → 34 美元 | 维持 | 购买 |
| 11/16/2020 | -9.83% | HC Wainwright & Co. | 34 美元 → 30 美元 | 维持 | 购买 |
| 07/27/2020 | 2.19% | HC Wainwright & Co. | → 34 美元 | 启动覆盖范围开启 | → 购买 |
| 05/01/2019 | -72.95% | Canaccord Genu | 11 美元 → 9 美元 | 维持 | 卖出 |
| 05/01/2019 | -66.94% | 派珀·桑德勒 | 15 美元 → 11 美元 | 升级 | 体重不足 → 中性 |
| 04/03/2019 | — | Canaccord Genu | 降级 | 持有 → 卖出 | |
| 2018 年 1 月 26 日 | -51.91% | Canaccord Genu | 14 美元 → 16 美元 | 维持 | 按住 |
Meridian Bioscience Questions & Answers
子午线生物科学问题与解答
The latest price target for Meridian Bioscience (NASDAQ: VIVO) was reported by HC Wainwright & Co. on July 8, 2022. The analyst firm set a price target for $34.00 expecting VIVO to rise to within 12 months (a possible 2.19% upside). 4 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2022年7月8日公布了子午线生物科学（纳斯达克股票代码：VIVO）的最新目标股价。这家分析公司将目标股价定为34.00美元，预计VIVO将在12个月内上涨至34.00美元（可能上涨2.19％）。去年有4家分析公司公布了评级。
The latest analyst rating for Meridian Bioscience (NASDAQ: VIVO) was provided by HC Wainwright & Co., and Meridian Bioscience downgraded their neutral rating.
Meridian Bioscience（纳斯达克股票代码：VIVO）的最新分析师评级由HC Wainwright & Co. 提供，Meridian Bioscience下调了中性评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Meridian Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Meridian Bioscience was filed on July 8, 2022 so you should expect the next rating to be made available sometime around July 8, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Meridian Bioscience的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。子午线生物科学的最新评级是在2022年7月8日提交的，因此您应该预计下一个评级将在2023年7月8日左右公布。
While ratings are subjective and will change, the latest Meridian Bioscience (VIVO) rating was a downgraded with a price target of $30.00 to $34.00. The current price Meridian Bioscience (VIVO) is trading at is $33.27, which is within the analyst's predicted range.
尽管评级是主观的，并将发生变化，但最新的子午线生物科学（VIVO）评级下调，目标股价为30.00美元至34.00美元。子午线生物科学（VIVO）目前的交易价格为33.27美元，在分析师的预测区间内。